Standard BioTools

Standard BioTools Long-term Debt

The Long-Term Debt of Standard BioTools (LAB) as of Oct 8, 2026 is 299,000.00 USD. In the previous year, Long-Term Debt was 299,000.00 USD — a change of 0.00% (lower).

Long-term Debt

299,000.00USD

YoY

0.00%

Last updated:

Long-Term Debt of Standard BioTools is 2025 299,000.00 USD. Long-Term Debt of Standard BioTools was 2024 299,000.00 USD. It decreases by 0.00% lower compared to the previous year.

The Standard BioTools Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
172.06 M USD
Jan 1, 2019
53.82 M USD
Jan 1, 2020
54.22 M USD
Jan 1, 2021
64.21 M USD
Jan 1, 2022
62.81 M USD
Jan 1, 2023
3.98 M USD
Jan 1, 2024
299,000.00 USD
Jan 1, 2025
299,000.00 USD
The Standard BioTools Long-term Debt history
YEARLong-term DebtYoY
299,000.00USD0.00%
299,000.00USD-92.49%
3.98 MUSD-93.66%
62.81 MUSD-2.18%
64.21 MUSD+18.41%
54.22 MUSD+0.75%
53.82 MUSD-68.72%
172.06 MUSD-11.87%
195.24 MUSD+0.15%
194.95 MUSD—
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Long-Term Debt of Standard BioTools is 299,000.00 USD in 2025.

Long-Term Debt of Standard BioTools changed from 299,000.00 USD to 299,000.00 USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools